Alzheimer’s disease antibody crenezumab doesn’t deliver in phase II trial

COPENHAGEN – Once more, an antiamyloid antibody has failed to live up to hopes for the treatment of Alzheimer’s disease.

Roche’s contender, crenezumab, faltered on all of the primary...